Mice injected intravenously with sheep erythrocytes (sRBC) demonstrate a transient increase in splenic cAMP levels (4-fold), which peak at 2 min after injection and return to basal levels by 20 min. In addition to the change in cAMP, an increase in splenic cGMP levels (1.5-fold) occurs beginning 5-10 min after sRBC injection, and persists for up' to 7 days. During this period cAMP levels remain at or below control levels in the spleen. There is no change in 3':5' cyclic nucleotide levels in the liver and a small increase (1.2-to 1.3-fold) in the thymus at the time when splenic cyclic nucleotide' levels are elevated. The changes in splenic cyclic nucleotide levels appear to be dependent on the presence of thymus-derived (T) lymphocytes, since little change occurs in cAMP and changes in cGMP are absent in athymic nude mice. In addition, cAMP levels were increased by pretreatment of normal mice with cortisone acetate, which selects for mature T lymphocytes. Agents that block autonomic nervous system functions have no effect on the early sRBC-induced changes in cyclic nucleotide levels. Indo.-methacin, an inhibitor of prostaglandin synthesis, reduces the change in cAMP levels by 50% and blocks the change in cGMP levels completely. Secondary stimulation with sRBC results in a larger increase in cAMP levels than that seen with a primary injection of sRBC, indicating the presence of specific antigen-sensitive memory cells. Changes in splenic cyclic nucleotide levels cannot be detected at early times after the injection of 1oluble' protein antigens such as bovine serum albumin and keyhole limpet hemocyanin. Salmonella H antigen stimulates a 2-fold increase in cAMP levels, the increase occurring more slowly than with sRBC. The in vivo changes in cyclic nucleotide levels are correlated with known changes in cyclic nucleotide levels which have been documented In vitro studies to date were concerned with the correlation of cyclic nucleotide levels and the effect of exogenous administration of cyclic nucleotides on the cellular aspects of immunoresponsiveness. The general conclusion to be drawn from this approach is that cGMP may be primarily involved in the proliferative aspects of the immune response (2), whereas cAMP appears to be antiproliferative but may be involved in
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The possible role of 3': 5' cyclic nucleotides in the induction and regulation of immune responses has been the subject of investigation in numerous laboratories (for review see ref. 1 ).
In vitro studies to date were concerned with the correlation of cyclic nucleotide levels and the effect of exogenous administration of cyclic nucleotides on the cellular aspects of immunoresponsiveness. The general conclusion to be drawn from this approach is that cGMP may be primarily involved in the proliferative aspects of the immune response (2) , whereas cAMP appears to be antiproliferative but may be involved in Abbreviations: cAMP, adenosine 3':5' cyclic monophosphate; cGMP guanosine 3': 5' cyclic monophosphate; sRBC, sheep erythrocytes; KLH, keyhole limpet hemocyanin; BSA, bovine serum albumin; T-cells, thymus-derived lymphocytes; B-cells, bonemarrow-derived lymphocytes. * Present address: Faculty of Pharmaceutical Sciences, Osaka University, Toneyama, Toyonaka, Osaka, Japan.
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other aspects of lymphocyte activation and maturation (3, 4) .
Until recently, few investigators had attempted to measure changes in cyclic nucleotide levels as a direct result of in vivo antigenic stimulation (5-7). Yamamoto et al. (5) and Plescia et al. (6) have reported that a rapid transient increase in cAMP levels occurs in antigen-stimulated mouse spleens. The increase appears to be antigen-specific and not the result of stress induced by animal manipulation or due to nonspecific phagocytosis (6) . These early studies demonstrate the relevance of examining in vivo cyclic nucleotide levels in relationship to the immune response.
The The neutralized supernatant was allowed to sit 2-24 hr at 4°. The resulting precipitate was removed by another centrifugation at 10,000 X g. The supernatant was then mixed with Dowex-formate (AG 1-X8 200400 mesh formate form, 100 ul/ml of supernatant), and repeatedly shaken over a 15-min period. Following this, the formate-Dowex suspension was centrifuged and the supernatant was discarded. The pellet was then washed three times with double-distilled water and then extracted twice with 4 N formic acid (redistilled). This procedure results in the release of both cAMP and cGMP from the formate-Dowex. The formic acid extract was then evaporated either in a rotary Evapomix or via lyophilization. The yields of cAMP and cGMP were 70-80% as estimated by recovery of radiolabeled cyclic nucleotides. While cAMP could be measured in cruder extracts, we have found it impossible to measure cGMP levels in lymphocytes accurately without following such an extraction procedure. The assay of cAMP was performed using the binding protein assay outlined by Gilman (8) ; cGMP was assayed by radioimmunoassay as outlined by Steiner et al. (9) .
RESULTS
Changes in Cyclic Nucleotide Levels in Mice Exposed to sRBC. Within 2 min after C57B1/6J mice are injected intravenously with an immunogenic dose of sRBC (2 X 108 per mouse), cAMP levels increase 3-to 4-fold (Fig. 1A) in the spleen. At the same time, cGMP levels decline slightly. Between 5-10 min postinjection, when cAMP levels are declining, cGMP levels increase (1.5-fold). While changes in spleen cAMP levels are rapid and transient, the changes that occur in the thymus are smaller and take place more slowly (Fig. 2) ; cAMP and cGMP levels in the thymus do not increase until 10 min, when the levels of both are slightly increased (1.2 to 1.5-fold). No change in cAMP levels was observed in the liver (Fig. 3) after sRBC injection at the time when changes are occurring in the spleen. Since both the spleen and liver are the major organs of clearance for particulate antigens, the lack of change in liver cyclic nucleotide levels indicate that such changes are not due to antigen clearance (10).
We have also investigated the long-term effects on splenic cyclic nucleotide levels after sRBC injection. From 1 to 12 hr after sRBC injection, splenic cAMP levels decline over the first 4 hr, returning to control levels by 12 hr. In contrast, splenic cGMP levels remain elevated during the same period. From day 1 to day 7 (Fig. 1C) , cAMP levels again decline to approximately 50% of control levels by day 4 and remain depressed through day 7, while cGMP levels remain elevated through day 7. Changes Each assay for cyclic nucleotide levels was performed in duplicate on extracts prepared from the spleens of the experimental animals as outlined in Materials and Methods. Four mice were used for each point and the values are reported as pmol/mg of protein ±t standard error. studied were KLH, BSA, and Salmonella H antigen, and the results are depicted in Table 1 . Two concentrations of each antigen, within ranges reported to be antigenic in mice, were used. The injection of KLH does not cause an increase in cAMP levels; BSA injection results in a slight suppression of cAMP levels; and Salmonella H antigen induces increases in cAMP levels, which rise significantly (1.5 to 2.0-fold) by 10 min. However, with this preparation of Salmonella H antigen the possibility of endotoxin contamination could explain the change observed (11) . At 10 min no significant increase in cGMP levels in the spleen could be detected after the injection of any of these antigens.
Further Characterization of Changes in Cyclic Nucleotide Levels in Response to sRBC. Since the early changes in cyclic nucleotide levels appear to be limited to lymphoid organs exposed to sRBC, it became important to demonstrate that this increase was due to an immunocompetent cell response. magnitude to subsequent exposure of a specific antigen, a priming dose of sRJ3C was administered. In these experiments, 1 X 106 sRBC was injected either 10 or 10 and 20 days before the experiments were performed. The mice were then injected with 1 X 108 sRBC. (This dose is lower than the usual 2 X 108 sRBC dose and it was used so that any difference in cyclic nucleotide levels between the different groups could be clearly detected.) The results depicted in Fig. 4 show that a single injection of 1 X 108 sRBC (curve a) results in a 1.5-fold increase in cAMP levels; one prior exposure (curve b) gives a 2.2-fold increase; and two prior exposures (curve c) results in nearly a 3-fold increase in spienic cAMP levels.
Experiments were also undertaken to determine the cell type involved. Since the sRBC response is T-cell dependent, these experiments were performed using T-cell-deficient nude mice and cortisone-treated mice, in which the composition of the splenic T-cell population is altered (12, 13) . Results obtained from an experiment in which nude mice were used are depicted in Table 2 . In this experiment, nu/nu females were compared to C57B1 as well as to Balb/c (the strain on which nu/nu trait is imposed). Two doses of sRBC were employed: for C57B1, 2 and the nude mice 1 X 109 sRBC were used. The higher dose of sRBC was used in order to be sure to detect any effect on the nude mice, since increasing doses in the normal mice give greater increases in splenic cAMP levels up to 1 X 109 sRBC. With the higher dose, the nude mice exhibited a far smaller relative increase in cAMP levels than did Balb/c at the same dose. It should be noted that the basal level of cAMP in nude mice is higher than that of the normal Balb/c. In all experiments performed with nude mice, no change in cGMP levels could be detected up to 20 min after sRBC injection. Cortisone acetate (2.5 mg per mouse intraperitoneally) was injected into C57Bl mice 48 hr prior to injection with sRBC. Table 2 shows that this treatment not only does not inhibit sRBC-induced elevation of cAMP levels, but produces an augmentation.
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To exclude autonomic nervous system effects to account for the increase in cAMP levels after sRBC injection, we in- 41. 6 ± 4.1 sRBC + phenoxybenzamine 49.5 ± 3.9 sRBC + propranolol 55.9 ± 5.2 Atropine 9. 2 ± 0. 5 Phenoxybenzamine 11. 8 ± 0. 6 Propranolol 6.6 ± 1. 1
Animals were killed 2 min after intravenous injection of 2 X 108 sRBC. Atropine (1 mg/kg), phenoxybenzamine (2 mg/kg), and propranolol (10 mg/kg) were injected intraperitoneally 2 hr before sRBC injection. Animals were killed 2 or 20 min after intravenous injection of 2 X 108 sRBC. Indomethacin (3 mg/kg) was injected (intraperitoneally) 24 hr as well as 2 hr prior to sRBC. * cAMP levels measured 2 min after injection of antigen. t cGMP levels measured 20 min after injection of antigen.
vestigated the influence in the sRBC response of agents that are known to block a and 1# adrenergic receptors, as well as an agent that blocks cholinergic receptors. The results are depicted in Table 3 . The mice were treated 2 hr prior to sRBC exposure with either phenoxybenzamine, propanolol, or atropine at doses known to block the relevant actions. None of these agents had an effect on the sRBC-induced increase in cAMP levels, with the possible exception of propranolol, which lowered cAMP levels in its saline-injected control, resulting in an even greater relative increase in cAMP levels. Also, no inhibition of sRBC-stimulated cGMP levels at 20 min was detected (data not shown). Indomethacin, a known inhibitor of prostaglandin synthesis (14) , was used to assess whether or not prostaglandins, which alter lymphocyte cyclic nucleotide levels in vitro (15) , were involved in the sRBC-induced changes in cyclic nucleotide levels. The data are depicted in Table 4 . In this experiment the increase in cAMP levels was inhibited 50% in mice treated with the drug. The cGMP changes were completely blocked. Subsequent experiments with indomethacin and another inhibitor of prostaglandin synthesis not only blocked sRBC-induced increases in splenic cyclic nucleotides but also altered several subsequent steps in the development of the immune response. T DISCUSSION We have presented evidence that after the intravenous injection of sRBC, there occurs in the spleen, within 2 min, a rapid rise in cAMP levels, which then decline by 10 min to control levels. Between 10 and 20 min splenic cGMP levels rise and remain elevated. During this same time period a small but significant increase in cyclic nucleotide levels occurs in the thymus (at 10 min), whereas no change is detected in liver cyclic nucleotide levels. These changes are dependent on the presence of T-cells, as shown by the experiments in athymic and cortisone-treated mice. Lack of autonomic nervous system involvement is indicated by the experiments using adrenergic and cholinergic blocking agents. A role for prostaglandins is suggested by the fact that indomethacin, which blocks prostaglandin synthesis, partially blocks the increase in cAMP and abolishes the increase in cGiMP levels.
To understand the relevance of these observations to the development of an immune-response it is necessary to con-* cAMP levels measured 2 min after injection of antigen. I D. R. Webb and A. T. Jamieson, manuscript in preparation.
sider the biological events associated with T-cell-dependent antigenic responses. After the exposure of an animal to antigen the sequence of events appears to be as follows: (1) clearance of antigens, (2) interaction of the antigen with a T-cell, (3) a macrophage-dependent triggering of the B-cell, probably with T-cell collaboration, and (4) B-cell proliferation and the production of antibody (10, 16) . The fact that erythrocyte antigens (sRBC, chicken erythrocytes) all elicit changes in cyclic nucleotide levels, while colloidal carbon and homologous mouse erythrocytes do not, argues strongly against the possibility that such changes are due to clearance. This is also supported by the data showing that no change in cyclic nucleotide levels occurs in the liver, the other major organ for antigen clearance (10) . It is possible to suggest that in the case of the soluble protein antigens KLH and BSA the lack of change in splenic cyclic nucleotide levels at an early time may be due to a difference in antigen processing for soluble versus -particulate antigens. For example, diffusion and dispersion of soluble antigens to areas other than the spleen (17) may make it difficult if not impossible to detect changes in cyclic nucleotide levels, due to different kinetics of antigen processing or slower and more gradual interaction with relevant antigensensitive T-and B-cells.
The interaction of the sRBC with T-cells leading to changes in cyclic nucleotide levels is strongly suggested by the data presented here, which depict the lack of large changes in cAMP levels and the absence of any change in cGMP levels in T-cell-deficient nude mice. This is supported by the experiments employing cortisone acetate, a drug that increases the relative numbers of mature T-cells (12) and leads to an augmentation of sRBC-induced changes in cAMP levels. The association of T-cells with the changes in cyclic nucleotide levels is probably not due to non-specific rosette formation (18), since we have been unable to induce such changes using resetting techniques in vitro (unpublished data). The results presented here are consistent with data presented by others (3) using in vitro systems to examine T-helper-cell functions.
Their data show that agents that raise intracellular cAMP levels in T-cells will augment T-helper-cell functions in a sRBC response in vitro. In addition, our data may provide an in vivo correlation to the work of Watson et al. (19) . They demonstrate that both cAMP and cGMP can augment in vitro responses to sRBC, cAMP being active only at the beginning of the response, cGMP being effective at both the early and later stages of the response. The early rise and decline in cAMP levels and the subsequent rise in cGMP levels is also consistent with data presented by other workers showing cAMP to be involved in maturational steps in cell development such as in T-cells (3, 4) . On the other hand, cGMP is primarily involved with proliferation, such as in T-and B-cell antigen-stimulated proliferation (2).
The ability to block the changes in splenic cyclic nucleotide levels with indomethacin implies a role for the prostaglandins in this system. Furthermore, it implicates prostaglandins as mediators in the development of the immune response to sRBC. Recent experiments show that by blocking sRBC-induced changes in cyclic nucleotide levels several subsequent steps in the developing immune response are severely restricted.
The sum of the work presented here shows that cyclic nucleotide levels may be altered by antigen (sRBC) in vivo in a manner consistent and correlative with a number of observations made with in vitro systems. The model we have developed may prove useful in further elucidation of the role of cyclic nucleotides and soluble mediators in the induction and development of the immune response.
